Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 31;7(1):77-82.
doi: 10.1007/s13340-015-0215-1. eCollection 2016 Mar.

Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus

Tomoyuki Iwasaki  1 , Masato Yoneda  2
Affiliations

Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus

Tomoyuki Iwasaki et al. Diabetol Int. .

Abstract

Aims: Our purpose was to clarify the predictive clinical characteristics of add-on therapy using dapagliflozin in patients with type 2 diabetes mellitus.

Methods: This single-center, open-label, pilot study was conducted in 50 patients with type 2 diabetes mellitus. They were treated with 50 mg dapagliflozin, once daily. A total of 46 patients were successfully followed over 12 weeks of treatment with dapagliflozin. They were assessed for several clinical parameters before the start of the study and at 12 weeks. Multiple linear regression analysis was used to search for independent predictors of reduction of hemoglobin A1c (HbA1c) levels after 12 weeks of dapagliflozin add-on treatment (ΔHbA1c).

Results: Dapagliflozin administration for 12 weeks resulted in significant reductions in baseline body mass index, systolic blood pressure, fasting plasma glucose, HbA1c, alanine aminotransferase, and uric acid. We were also able to show that HbA1c levels and low-density lipoprotein cholesterol (LDL-C) significantly correlated with ΔHbA1c. Furthermore, multiple linear regression analysis showed that baseline HbA1c and LDL-C significantly correlated with ΔHbA1c.

Conclusion: Our prospective 12-week study showed that baseline HbA1c and LDL-C significantly contribute to the HbA1c-lowering effect of dapagliflozin.

Trial registration: UMIN Clinical Trials Registry (UMIN000014922).

Keywords: Dapagliflozin; Predictive clinical characteristics; Sodium-glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient attrition
Fig. 2
Fig. 2
Distribution plots of a ΔHbA1c (%) versus baseline HbA1c and b baseline LDL cholesterol
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Brunton SA. Hypoglycemic potential of current and emerging pharmacotherapies in type 2 diabetes mellitus. Postgrad Med. 2012;124:74–83. doi: 10.3810/pgm.2012.07.2570. - DOI - PubMed
    1. Morgan CL, Jenkins-Jones S, Evans M, et al. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab. 2012;14:424–432. doi: 10.1111/j.1463-1326.2011.01552.x. - DOI - PubMed
    1. Mudaliar S, Chang AR, Aroda VR, et al. Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes. Diabetes Obes Metab. 2010;12:133–138. doi: 10.1111/j.1463-1326.2009.01126.x. - DOI - PubMed
    1. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657. doi: 10.2337/dc08-1863. - DOI - PMC - PubMed
    1. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–415. doi: 10.7326/0003-4819-156-6-201203200-00003. - DOI - PubMed

LinkOut - more resources